Novel biologic therapies in relapsed or refractory diffuse large B cell lymphoma: CAR-T is not the only answer.

Abstract

Patients with diffuse large B-cell lymphoma who have refractory or relapsed disease following first line treatment have a poor prognosis when treated with conventional therapies. Significant efforts have been made in recent years to bring a broad spectrum of novel targeted therapies, the most noteworthy of which is chimeric antigen receptor T-cell therapy (CAR-T). Not all patients are eligible for CAR-T given the relatively high risk of complications and limited availability. Here we discuss promising novel biologic therapies that have been introduced in the last few years and go over ongoing clinical trials in the field.

Keywords

• Diffuse large B cell lymphoma
• Immunotherapy
• Novel agents
• Bispecific antibodies
• Antibody drug conjugates